美康生物
(300439)
| 流通市值：29.38亿 | | | 总市值：38.62亿 |
| 流通股本：2.92亿 | | | 总股本：3.84亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 376,022,696.88 | 1,539,159,714.69 | 1,135,669,290.81 | 736,221,523.12 |
| 营业收入 | 376,022,696.88 | 1,539,159,714.69 | 1,135,669,290.81 | 736,221,523.12 |
| 二、营业总成本 | 351,135,278.16 | 1,516,898,858.66 | 1,105,821,644.63 | 706,593,829.78 |
| 营业成本 | 231,437,715.5 | 972,738,132.3 | 685,534,462.38 | 435,849,307.36 |
| 税金及附加 | 4,316,678.96 | 19,075,191.02 | 13,983,514.19 | 9,213,656.6 |
| 销售费用 | 52,650,643.01 | 225,502,634.4 | 171,847,447 | 104,496,129.65 |
| 管理费用 | 33,838,780.56 | 173,193,201.12 | 133,212,873.01 | 86,924,656.62 |
| 研发费用 | 28,846,722.25 | 127,196,766.84 | 103,113,005.51 | 71,451,238.98 |
| 财务费用 | 44,737.88 | -807,067.02 | -1,869,657.46 | -1,341,159.43 |
| 其中:利息费用 | 152,965.28 | 2,567,315.64 | 1,147,601.83 | 108,446.4 |
| 其中:利息收入 | 551,633.04 | 3,875,904.19 | 2,996,194.74 | 2,261,671.46 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 756,930.68 | 430,440.4 | 899,739.61 | 226,892.6 |
| 加:投资收益 | 891,298.04 | 8,724,190.36 | 2,372,271.46 | 2,342,205.59 |
| 资产处置收益 | - | 1,659,738.98 | 13,265.65 | 2,981.27 |
| 资产减值损失(新) | -341,683.06 | -32,934,184.75 | -2,534,106.76 | -2,404,571.43 |
| 信用减值损失(新) | -247,199.37 | -6,820,931.29 | -7,927,839.64 | -1,303,489.6 |
| 其他收益 | 11,663,856.61 | 39,945,112.09 | 31,430,676.94 | 26,110,145.41 |
| 四、营业利润 | 37,610,621.62 | 33,265,221.82 | 54,101,653.44 | 54,601,857.18 |
| 加:营业外收入 | 5,871.87 | 14,393,470.78 | 798,680.4 | 3,334,903.38 |
| 减:营业外支出 | 640,095.25 | 1,566,046.34 | 1,493,753.83 | 992,787.6 |
| 五、利润总额 | 36,976,398.24 | 46,092,646.26 | 53,406,580.01 | 56,943,972.96 |
| 减:所得税费用 | 3,788,400.12 | -15,269,330.52 | -5,486,989.04 | 1,335,896.63 |
| 六、净利润 | 33,187,998.12 | 61,361,976.78 | 58,893,569.05 | 55,608,076.33 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 33,187,998.12 | 61,361,976.78 | 58,893,569.05 | 55,608,076.33 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 33,766,362.28 | 63,201,459.62 | 60,533,779.47 | 56,833,722.63 |
| 少数股东损益 | -578,364.16 | -1,839,482.84 | -1,640,210.42 | -1,225,646.3 |
| 扣除非经常损益后的净利润 | 23,145,176.7 | 15,456,921.15 | 31,206,714.01 | 30,024,575.42 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.09 | 0.16 | 0.16 | 0.15 |
| (二)稀释每股收益 | 0.09 | 0.16 | 0.16 | 0.15 |
| 八、其他综合收益 | 737,416.79 | -628,731.08 | 1,261,533.54 | 1,302,862.97 |
| 归属于母公司股东的其他综合收益 | 375,818.74 | -1,014,070.39 | 1,037,302.33 | 1,063,056.7 |
| 九、综合收益总额 | 33,925,414.91 | 60,733,245.7 | 60,155,102.59 | 56,910,939.3 |
| 归属于母公司股东的综合收益总额 | 34,142,181.02 | 62,187,389.23 | 61,571,081.8 | 57,896,779.33 |
| 归属于少数股东的综合收益总额 | -216,766.11 | -1,454,143.53 | -1,415,979.21 | -985,840.03 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-29 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |